Gilead Sciences (GILD) delivered mixed results in FY2026 on revenue of $137.9B versus the $135.2B estimate (+6.6% YoY) and EPS of $2.96. Below is the full Gilead Sciences earnings breakdown — the risk-adjusted verdict, price forecast, technicals, options and hedge-fund 13F holdings, decoded in plain English.
$137.9B (vs $135.2B est · +2.0% surprise · +6.6% YoY)
EPS
$2.96 (vs $3.08 est · -3.9% surprise · +31.4% YoY)
Share price
$147.87 (-0.5%)
Market cap
$1.85T
What you'll find
Next Gilead Sciences (GILD) earnings date, the expected move and the estimates priced in
A clear Beat / Miss / In-line / Mixed verdict the moment Gilead Sciences reports
Revenue & EPS versus estimates, guidance and segment trends
Multi-lens price forecast — analyst, quant, technical and options views
Deep research: red flags, risk decoder and earnings-call sentiment
Technicals, options / implied volatility and unusual-activity signals
Hedge-fund and legendary-investor 13F holdings in Gilead Sciences (GILD)
Side-by-side peer and historical earnings comparison
Frequently asked questions
When is Gilead Sciences's next earnings date?
Gilead Sciences's (GILD) next scheduled earnings date is Jan 30, 2025. Magnisto shows the confirmed date, the options-implied expected move and the revenue and EPS estimates Wall Street is modeling into the report.
Did Gilead Sciences (GILD) beat or miss earnings?
In FY2026, Gilead Sciences (GILD) posted mixed results — revenue of $137.9B versus the $135.2B estimate (+2.0% surprise) and EPS of $2.96 versus $3.08 expected (-3.9% surprise). Magnisto decodes every Gilead Sciences (GILD) report into a clear Beat, Miss, In-line or Mixed verdict and checks whether guidance was raised, held or cut.
What is the forecast for Gilead Sciences (GILD) stock?
Magnisto blends analyst price targets, quantitative research, technical trend and options-implied moves into a scenario range for Gilead Sciences (GILD), anchored to the current $147.87 share price, so you can weigh the bull, base and bear cases for Gilead Sciences side by side.
Is Gilead Sciences (GILD) a buy right now?
Magnisto does not give buy or sell tips. It gives you the institutional-grade evidence — the verdict, valuation, risks, technicals and hedge-fund 13F flows — so you can decide whether Gilead Sciences fits your own thesis and risk profile. This is research, not investment advice.